Minerva Neurosciences
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2007-01-01
- Employees
- 9
- Market Cap
- $19.3M
- Introduction
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.
A Study to Evaluate the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of Co-Administration of Roluperidone and Olanzapine in Adult Subjects With Moderate to Severe Negative Symptoms of Schizophrenia
- Conditions
- Negative Symptoms in Schizophrenia
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 17
- Registration Number
- NCT06107803
- Locations
- 🇺🇸
Collaborative Neuroscience Research, LLC, Garden Grove, California, United States
🇺🇸CBH Health, LLC, Gaithersburg, Maryland, United States
🇺🇸Hassman Research Institute, Marlton, New Jersey, United States
A Study to Evaluate the Efficacy and Safety of MIN-117 in Adult Patients With Major Depressive Disorder
- Conditions
- Major Depressive Disorder
- Interventions
- Drug: MIN-117 2.5 mgDrug: PlaceboDrug: MIN-117 5.0 mg
- First Posted Date
- 2018-02-27
- Last Posted Date
- 2020-12-17
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 360
- Registration Number
- NCT03446846
- Locations
- 🇺🇸
Woodland International Research Group, LLC, Little Rock, Arkansas, United States
🇺🇸Pacific Clinical Research Medical Group, Upland, California, United States
🇺🇸Neurobehavioral Research, Inc, Cedarhurst, NY, Cedarhurst, New York, United States
Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia
- Conditions
- Negative Symptoms of Schizophrenia
- Interventions
- First Posted Date
- 2018-01-11
- Last Posted Date
- 2023-04-28
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 515
- Registration Number
- NCT03397134
- Locations
- 🇺🇸
Collaborative Neuroscience Network, LLC., Torrance, California, United States
🇺🇸Atlanta Center for Medical Research, Atlanta, Georgia, United States
🇺🇸Uptown Research Institute LLC, Chicago, Illinois, United States
A Pharmacokinetic Study of MIN-101 and Its Metabolites in Healthy Subjects to Compare MIN-101 in Poor and Extensive Metabolizers
- Conditions
- Healthy Subjects
- Interventions
- Drug: MIN-101
- First Posted Date
- 2017-03-07
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 23
- Registration Number
- NCT03072056
- Locations
- 🇮🇪
Biokinetic Europe, Belfast, Ireland
A Pharmacokinetic Study of Modified Release (MR) Formulations of MIN-101 in Healthy Subjects
- Conditions
- Healthy Subjects
- Interventions
- Drug: MIN-101
- First Posted Date
- 2017-02-01
- Last Posted Date
- 2017-08-31
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 14
- Registration Number
- NCT03038646
- Locations
- 🇮🇪
Biokinetic Europe, Belfast, Ireland
Pharmacokinetic Study of MIN-101 in Healthy Subjects
- Conditions
- Schizophrenia
- Interventions
- Drug: MIN-101Drug: Placebo
- First Posted Date
- 2014-09-05
- Last Posted Date
- 2015-02-24
- Lead Sponsor
- Minerva Neurosciences
- Target Recruit Count
- 32
- Registration Number
- NCT02232529
- Locations
- 🇬🇧
Quotient Clinical, Ruddington, Nottingham, United Kingdom